Journal List > J Korean Soc Endocrinol > v.20(6) > 1063833

J Korean Soc Endocrinol. 2005 Dec;20(6):608-615. Korean.
Published online December 20, 2005.  https://doi.org/10.3803/jkes.2005.20.6.608
Copyright © 2005 Korean Endocrine Society
Osteoporosis and Atherosclerosis: Current and New Potential Medicines Targeting Both Diseases
Sung-Kil Lim and So Young Park
Department of Internal Medicine, Yonsei University College of Medicine, Korea.

Figures


Figure 1
Mevalonic acid pathway and action sites of statins and bisphosphonates.
Click for larger image


Figure 2
The involvements of PTH, PTHrP, and their shared PTHR1 receptor in vascular ossification.
Click for larger image

References
1. Whitney C, Warburton D, Frohlich J, Chan S, McKay H, Khan K. Are cardiovascular disease and osteoporosis directly linked? Sports Med 2004;34:779–807.
2. Mundy G, Garrett R, Harris S, Chan J, Chen D, Rossini G, Boyce B, Zhao M, Gutierrez G. Stimulation of bone formation in vitro and in rodents by statins. Science 1999;286:1946–1949.
3. Maritz F, Conradie M, Hulley P, Gopal R, Hough S. Effect of statins on bone mineral density and bone histomorphometry in rodents. Arteriosclrer Thromb Vasc Biol 2001;21:1636–1641.
4. Meier C, Schlienger R, Kraenzlin M, Schlegel B, Jick H. HMG-CoA reductase inhibitors and the risk of fractures. JAMA 2000;283:3205–3210.
5. Mundy G. Statins and their potential for osteoporosis. Bone 2001;29:495–497.
6. Watanabe S, Fukumoto S, Takeuchi Y, Fujita H, Nakano T, Fujita T. Effects of 1-year treatment with fluvastatin or pravastatin on bone. Am J Med 2001;110:584–587.
7. LaCroix A, Cauley J, Pettinger M, Hsia J, Bauer D, McGowan J, Chen Z, Lewis C, McNeeley G, Passaro M, Jackson R. Statin Use, Clinical Fracture, and Bone Density in Postmenopausal Women: Results from the Women's Health Initiative Observational Study. Ann Intern Med 2003;139:97–104.
8. Adami S, Braga V, Guidi G, Gatti D, Gerardi D, Fracassi E. Chronic intravenous aminobisphosphonate therapy increases high-density lipoprotein cholesterol and decreases low-density lipoprotein cholesterol. J Bone Miner Res 2000;15:599–604.
9. Rogers M, Gordon S, Benford H, Coxon F, Luckman S, Monkkonen J, Frith J. Cellular and Molecular Mechanisms of Action of Bisphosphonates. Cancer 15;88:2961–2978.
10. Ylitalo R. Bisphosphonates and atherosclerosis. Gen Pharm 2002;35:287–296.
11. Kramsch D, Aspen A, Rozler L. Atherosclerosis: prevention by agents not affecting abnormal levels of blood lipids. Science 1981;213:1511–1512.
12. Koshiyama H, Nakamura Y, Tanaka S, Minamikawa J. Decrease in carotid intima-media thickness after 1-year therapy with Etidronate for osteopenia associated with type 2 diabetes. J Clin Endocrinol Metab 2005;85:2793–2796.
13. Tankó L, Qin G, Alexandersen P, Bagger Y, Christiansen C. Effective doses of ibandronate do not influence the 3-year progression of aortic calcification in elderly osteoporotic women. Osteoporos Int 2005;16:184–190.
14. Shimshi M, Abe E, Fisher E, Zaidi M, Fallon J. Bisphosphonates induce inflammation and rupture of atherosclerotic plaques in apolipoprotein-E null mice. Biochem Biophys Res Commun 2005;328:790–793.
15. Barrett-Connor E, Cox D, Anderson P. The potential of SERMs for reducing the risk of coronary heart disease. Trends Endocrinol Metab 1999;10:320–325.
16. Williams J, Wagner J, Li Z, Golden D, Adams M. Tamoxifen inhibits arterial accumulation of LDL degradation products and progression of coronary artery atherosclerosis in monkeys. Arterioscler Thromb Vasc Biol 1997;17:403–408.
17. Ke H, Chen H, Simmons H, Qi H, Crawford D, Pirie C, Chidsey-Frink K, Ma Y, Jee W, Thompson D. Comparative effects of droloxifene, tamoxifen, and estrogen on bone, serum cholesterol, and uterine histology in the ovariectomized rat model. Bone 1997;20:31–39.
18. Figtree G, Lu Y, Webb C, Collins P. Raloxifene Acutely Relaxes Rabbit Coronary Arteries In Vitro by an Estrogen Receptor - Dependent and Nitric Oxide - Dependent Mechanism. Circulation 1999;100:1095–1101.
19. Zuckerman S, Bryan N. Inhibition of LDL oxidation and myeloperoxidase dependent tyrosyl radical formation by the selective estrogen receptor modulator raloxifene. Atherosclerosis 1996;126:65–75.
20. Walsh B, Kuller L, Wild R, Paul S, Farmer M, Lawrence J, Shah A, Anderson P. Effects of Raloxifene on Serum Lipids and Coagulation Factors in Healthy Postmenopausal Women. JAMA 1998;279:1445–1451.
21. Stamatelopoulos K, Lekakis J, Poulakaki N, Papamichael C, Venetsanou K, Aznaouridis K, Protogerou A, Papaioannou T, Kumar S, Stamatelopoulos S. Tamoxifen improves endothelial function and reduces carotid intima-media thickness in postmenopausal women. Am Heart J 2004;147:1093–1099.
22. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998;351:1451–1467.
23. Mosca L, Barrett-Connor E, Wegner N, Collins P, Grady D, Kornitzer M, Moscarelli E, Paul S, Wright T, Helterbrand J, Anderson P. Design and methods of the Raloxifene Use for the Heart (RUTH) study. Am J Cardiol 2001;88:392–395.
24. Hamerman D. Osteoporosis and atherosclerosis: biological linkages and the emergence of dual-purpose therapies. Q J Med 2005;98:467–484.
25. Kontogianni M, Dafni U, Routsias J, Skopouli F. Blood leptin and adiponectin as possible mediators of the relation between fat mass and BMD in perimenopausal women. J Bone Miner Res 2004;19:546–551.
26. Akune T, Ohba S, Kamekura S, Yamaguchi M, Chung U, Kubota N, Terauchi Y, Harada Y, Azuma Y, Nakamura K, Kadowaki T, Kawaguchi H. PPARgamma insufficiency enhances osteogenesis through osteoblast formation from bone marrow progenitors. J Clin Invest 2004;113:846–855.
27. Ali A, Weinstein R, Stewart S, Parfitt A, Manolagas S, Jilka R. Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation. Endocrinology 2005;146:1226–1235.
28. Whitfield J. Osteogenic PTHs and vascular ossification-Is there a danger for osteoporotics? J Cell Biochem 2005;95:437–444.
29. Martin-Ventura JL, Ortego M, Esbrit P, Hernandez-Presa MA, Ortega L, Egido J. Possible role of parathyroid hormone-related protein as a proinflmammatory cytokine in atherosclerosis. Stroke 2003;34:1783–1789.
30. Shao J, Cheng S, Charlton-Kachigian N, Loewy A, Towler D. Teriparatide (Human Parathyroid Hormone (1-34)) inhibits osteogenic vascular calcification in diabetic low density lipoprotein receptor-deficient mice. J Biol Chem 2003;278:50195–50202.
31. Sattler A, Schoppet M, Schaefer J, Hofbauer L. Novel aspects on RANKL ligand and osteoprotegerin in osteoporosis and vascular disease. Calcif Tissue Int 2004;74:103–106.
32. Price P, June H, Buckley J, Williamson M. Osteoprotegerin inhibits artery calcification induced by warfarin and by vitamin D. Arterioscler Thromb Vasc Biol 2001;21:1610–1616.
33. Browner W, Lui L, Cummings S. Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women. J Clin Endocrinol Metab 2001;86:631–637.
34. Schoppet M, Schaefer J, Hofbauer L. Low serum levels of soluble RANK ligand are associated with the presence of coronary artery disease in men. Circulation 2003;107:76.
35. Schoppet M, Preissner K, Hofbauer L. RANK ligand and osteoprotegerin paracrine regulators of bone metabolism and vascular function. Arterioscler Thromb Vasc Biol 2002;22:549–553.
36. Bekker P, Holloway D, Nakanishi A, Arrighi M, Leese P, Dunstan C. The effect of a single dose of osteoprotegerin in postmenopausal women. J Bone Miner Res 2001;16:348–360.
37. Klein R, Allard J, Avnur Z, Nikolcheva T, Rotstein D, Carlos A, Shea M, Waters R, Belknap J, Peltz G, Orwoll E. Regulation of bone mass in mice by the lipoxygenase gene Alox15. Science 2004;303:229–232.
38. Cornicelli J, Trivedi B. 15-Lipoxygenase and its inhibition: a novel therapeutic target for vascular disease. Curr Pharm Des 1999;5:11–20.
39. Magoori K, Kang M, Ito M, Kakuuchi H, Ioka R, Kamataki A, Kim D, Asaba H, Iwasaki S, Takei Y, Sasaki M, Usui S, Okazaki M, Takahashi S, Ono M, Nose M, Sakai J, Fujino T, Yamamoto T. Severe hypercholesterolemia, impaired fat tolerance, and advanced atherosclerosis in mice lacking both low density lipoprotein receptor-related protein 5 and apolipoprotein E. J Biol Chem 2003;278:11331–11336.